All Episodes
Oncology Today with Dr Neil Love — 523 episodes · page 5 of 6
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
Second Opinion: Urologic Oncology Investigators Discuss How They Apply Clinical Research in the Care of Patients with Urothelial Bladder Cancer
Key Presentations on Lymphoma from Recent Major Conferences
Bispecific Antibodies in the Management of Multiple Myeloma
Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
Virtual Case Library: Metastatic Triple-Negative Breast Cancer
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition
Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria
Special Edition – Prostate Cancer Updates from a CME Program Held at the 2024 Genitourinary Cancers Symposium
Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition
Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer
The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma
Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer
Consensus or Controversy? Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers — A 2024 Post-ASCO Gastrointestinal Cancers Symposium Review
Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
Virtual Case Library: Metastatic Urothelial Bladder Cancer
Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Gastroesophageal Cancers
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia
Consensus or Controversy? Investigator Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Hepatobiliary Cancers
Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 4 of a 4-Part Series
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part Series
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series
Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition
Inside the Issue: Targeted and Immunotherapeutic Approaches for Biliary Tract Cancers
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 3 of a 3-Part Series
Implications of Recent Data Sets for the Current and Future Management of Breast Cancer
Implications of Recent Data Sets for the Current and Future Management of Gynecologic Cancers
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 2 of a 3-Part Series
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series
Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 2 of a 4-Part Series
Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer
Meet The Professor: Optimizing the Management of Gastroesophageal Cancers — Part 1 of a 3-Part Series
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer
Management of Metastatic Pancreatic Cancer with Dr Michael Pishvaian
Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar
Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 1 of a 4-Part Series
What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma
Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer
Blastic Plasmacytoid Dendritic Cell Neoplasm
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma
Novel Agents and Strategies in the Treatment of Ovarian Cancer
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
Optimizing the Management of Metastatic Pancreatic Cancer
The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma
Meet The Professor: Optimizing the Management of Melanoma
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy
The Implications of Recent Data Sets for the Management of Hepatocellular Carcinoma
Exploring the Current and Future Management of High-Risk, Hormone-Sensitive Nonmetastatic Prostate Cancer
Role of BTK Inhibitors in Therapy for Mantle Cell Lymphoma
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series
Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences
Special Edition — Key Presentations on Genitourinary Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor
Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management
Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia
Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers
Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Gastrointestinal Cancers Issue
Special Edition — Key Presentations on Gynecologic Cancers from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer — A Clinical Investigator Think Tank
Optimizing the Management of Metastatic Urothelial Bladder Cancer
Special Edition — Current and Future Management of Breast Cancer
Special Edition — Key Presentations from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ovarian Cancer Issue
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Colorectal and Gastroesophageal Cancers
Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes
Immune Thrombocytopenia Edition with Dr Hanny Al-Samkari
Paroxysmal Nocturnal Hemoglobinuria Edition with Dr Carlos de Castro
Special Edition — Management of Hepatobiliary Cancers
Special Edition — Management of Urothelial Bladder Cancer
Special Edition — Current and Future Management of Breast Cancer
Special Nursing Edition — What I Tell My Patients About New Treatments and Clinical Trials in Urothelial Bladder Cancer
The Implications of New Research Findings for the Management of Endometrial Cancer
Meet The Professor: The Current and Future Management of Hodgkin and Non-Hodgkin Lymphoma
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2 - Part Series
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition
Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Management of Desmoid Tumors with Dr Mrinal Gounder
Management of HER2-Altered Non-Small Cell Lung Cancer
Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation
Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting — With Dr Srdan Verstovsek